Market Newsdesk

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Civitas you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/civitas-resources-inc
.

Investors have until July 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Civitas securities.   The case is pending in the U.S. District Court for the District of New Jersey and is captioned Lin v. Civitas Resources., et al., No. 25-cv-03791.

Why was Civitas Sued for Securities Fraud?

Civitas is an oil and gas exploration and production company with its key assets located in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico. The complaint alleges that Civitas stated that both basins had “enhanced recovery potential” and that it had “driven production ahead of plans,” while touting “enhanced margins through reduced operating costs” and insisting that “costs are below expectations.”

In truth, the Company’s oil production peaked in 2024, and increasing production would require Civitas to spend significant capital to acquire additional land, driving up costs.

The Stock Declines as the Truth is Revealed

On February 24, 2025, Civitas announced disappointing Q4 and full year 2024 results, and reduced its oil production guidance. The Company explained that oil production had peaked and it would need to spend hundreds of millions of dollars to acquire thousands of acres of new land to produce more oil. Civitas also announced that it was implementing a 10% reduction in its workforce to “solidify the Company’s low-cost structure.” On the same day, Civitas announced the immediate firings of its Chief Operating Officer and Chief Transformation Officer. On this news, the price of Civitas stock declined more than 18%, from a closing price of $49.30 per share on February 24, 2025, to $40.35 per share on February 25, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/civitas-resources-inc

.

What Can You Do?

If you invested in Civitas you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/civitas-resources-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/civitas-resources-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fluence Energy, Inc. (NASDAQ: FLNC) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Fluence Energy, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/fluence-energy-inc
.

Investors have until May 12, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fluence Energy common stock. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned Abramov v. Fluence Energy, Inc., et al., No. 25-cv-00444.

Why was
Fluence Energy
Sued for Securities Fraud?

Fluence Energy offers energy storage products and solutions, delivery services, recurring operational and maintenance services, and digital applications and solutions for energy storage and other power assets.

As alleged, Fluence Energy misrepresented the strength of its competitive position, sales pipeline, and backlog of orders. In reality, Fluence Energy concealed declines in its sales and earnings growth by engaging in aggressive revenue pull-forwards and selectively applied earnings adjustments.

The Stock Declines as the Truth is Revealed

On February 22, 2024, Blue Orca Capital issued a report revealing that Siemens Energy—an affiliate of one of the company’s founders and largest sources of revenue—filed a lawsuit accusing Fluence Energy of misrepresentations, breach of contract, and fraud. The Blue Orca report also revealed that much of Fluence Energy’s sales and earnings growth was the result of aggressive revenue pull-forwards and selectively applied earnings adjustments.

Then, on February 10, 2025, Fluence Energy issued a press release announcing its financial results for Q1 2025. Fluence Energy reported a net loss of $57 million, or $0.32 per share, with revenues falling 49% year-over-year, and lowered its revenue guidance for the remainder of the year. According to Fluence Energy, “[w]e have experienced customer-driven delays in signing certain contracts that, coupled with competitive pressures, result in the need to lower our fiscal year 2025 outlook.”

This news caused the price of Fluence Energy stock to decline 46%, to close at $7.00 per share on February 11, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/fluence-energy-inc

.

What Can You Do?

If you invested in Fluence Energy you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/fluence-energy-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/fluence-energy-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against The Bancorp, Inc. (NASDAQ: TBBK) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Bancorp, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/the-bancorp-inc
.

Investors have until May 16, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Bancorp stock. The case is pending in the U.S. District Court for the District of Delaware and is captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326.

Why was Bancorp Sued for Securities Fraud?

Bancorp is a financial holding company that engages in institutional banking, commercial real estate bridge lending, small business lending and commercial fleet leasing. Its commercial real estate bridge loans (“REBLs”) are primarily collateralized by apartment buildings.

The complaint alleges that Bancorp misrepresented the significant risk of default or loss on its REBL loan portfolio and that its credit loss methodology was insufficient to account for the allowance of credit losses. As alleged, Bancorp also misrepresented the effectiveness of its internal controls over financial reporting as they contained at least one material weakness.

The Stock Declines as the Truth is Revealed

On March 21, 2024, Culper Research issued a report stating that Bancorp had misrepresented the significant risks of default and/or loss on certain Bancorp REBL loans. According to Culper Research, Bancorp’s REBL loan portfolio is filled with apartments which are “quite literally, crumbling,” with high vacancies and multiple condemnations and that its portfolio consisted of loans to unsophisticated borrowers who were coaxed by “get rich quick” promises. This news caused the price of Bancorp stock to decline over 10%, from $36.04 per share on March 21, 2024, to $32.12 per share on March 21, 2024.

On October 24, 2024, Bancorp announced its Q3 2024 results, disclosing net income of only $51.5 million due to “a new CECL [current expected credit losses methodology] factor” to REBL loans which increased credit losses and resulted in a post-tax reduction in net income of $1.5 million. This news caused the price of Bancorp stock to decline over 14%, from $54.96 per share on October 24, 2025, to $47.01 per share on October 25, 2025.

Finally, on March 4, 2025, Bancorp disclosed that it had “inappropriately filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024” and informed investors that its financial statements from 2022 to 2024 as reflected in that Annual Report should no longer be relied upon. Bancorp revealed that its auditors did not approve the use of its audit opinions for those years. This news caused the price of Bancorp stock to decline 4.4%, from $53.59 per share on March 4, 2025, to $51.25 per share on March 5, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/the-bancorp-inc

.

What Can You Do?

If you invested in Bancorp you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/the-bancorp-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/the-bancorp-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Viatris, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/viatris-inc
.

Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities.   The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466.

Why was Viatris Sued for Securities Fraud?

Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in “good operating condition,” were “suitable for their intended purposes,” and that the Company was “committed to maintaining the highest quality manufacturing standards.”

However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company’s Indore, India, facility. Still, Viatris downplayed the situation, describing it as a “little bit of headwind” and spoke about “active discussions with the FDA” to get additional products produced at the facility exempted from the FDA’s Import Alert.

In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company’s financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide.

The Stock Declines as the Truth is Revealed

On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the “negative impact” of the Indore facility’s failed inspection would lower 2025 revenue by “approximately $500 million” and 2025 earnings from operations by “approximately $385 million.” The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/viatris-inc

.

What Can You Do?

If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/viatris-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/viatris-inc

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc
.

Investors have until June 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased BigBear.ai securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned Priewe v. BigBear.ai Holdings, Inc., et al., No. 25-cv-00623.

Why was BigBear.ai Sued for Securities Fraud?

BigBear.ai is an AI-driven technology solutions company that helps organizations operationalize AI by analyzing complex data and providing actionable insights in areas of national security, supply chain management, and digital identity and biometrics solutions. 

BigBear.ai went public via a special purpose acquisition company (“SPAC”) transaction, completing merging first with GigCapital4 Merger Sub Corporation, and subsequently with GigCapital4, Inc. Upon completion of the merger, BigBear.ai issued $200 million of unsecured convertible notes with a maturity date of December 15, 2026. During the relevant period, BigBear.ai improperly accounted for the 2026 Convertible Notes, causing it to misstate various items in several of the Company’s previously issued financial statements.

The Stock Declines as the Truth is Revealed

On March 18, 2025, BigBear.ai delayed the filing of its 2024 10K, disclosing that certain of the Company’s financial statements since fiscal year 2021 should no longer be relied upon and would be restated. On this news, the price of BigBear.ai stock declined roughly 15%, from a closing price of $3.49 per share on March 17, 2025, to $2.97 per share on March 18, 2025.

Then, on March 25, 2025, after market, BigBear filed its 2024 10-K restating its consolidated financial statements “to reflect the issuance of the 2026 Notes Conversion Option at fair value as of December 7, 2021 and the subsequent remeasurement to fair value at each reporting date.” The 2024 10-K also disclosed that the Company had identified a material weakness in its internal control over financial reporting. On this news, the price of BigBear.ai stock declined roughly 9%, from a closing price of $3.51 per share on March 25, 2025, to $3.19 per share on March 26, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc

.

What Can You Do?

If you invested in BigBear.ai you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc

Attorney advertising. Past results do not guarantee future outcomes.

SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializing novel pharmaceuticals to provide patients with better, safer and more accessible medicines.

Under the terms of the licensing and commercialization agreement, LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia, including Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore.

“We are very excited to partner with the team at Lotus to bring LNZ100 to Southeast Asia, given their proven track record for successful global partnerships, robust commercial infrastructure in the region and six consecutive years of double-digit revenue growth, now exceeding USD $500 million. Upon approval, we look forward to the Lotus team bringing LNZ100 to this important and commercially attractive region,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “We are committed to partnering with leading commercial pharmaceutical companies ex-US, providing access to LNZ100 for patients worldwide.”

Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented: “We are very pleased to be the trusted partner of LENZ to help bring such a transformative product that will significantly enhance the lives of more than 100 million people in this region who are currently impacted by presbyopia. Our commitment to excellence drives us to diligently pursue the necessary regulatory approvals and eventually leverage our extensive network of channels to ensure seamless access to this life-altering solution. Our dedication to innovation and safety remains unwavering as we continuously strive to provide better and safer pharmaceuticals to the markets that we serve.”    

In October 2024, LENZ announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application.

About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness

ASHBURN, Va., May 09, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2025 first quarter financial results on its investor relations website at https://investors.telos.com.

Telos will host a live webcast to discuss its first quarter 2025 financial results today, May 9, 2025, at 9:30 a.m. ET. To access the webcast, visit https://edge.media-server.com/mmc/p/araocu99.

Related presentation materials will be made available on the Investors section of the Company’s website at https://investors.telos.com. In addition, an archived webcast will be available approximately two hours after the conclusion of the live event on the Investors section of the Company’s website. 

About Telos Corporation

Telos Corporation (NASDAQ: TLS) empowers and protects the world’s most security-conscious organizations with solutions for continuous security assurance of individuals, systems, and information. Telos’ offerings include cybersecurity solutions for IT risk management and information security; cloud security solutions to protect cloud-based assets and enable continuous compliance with industry and government security standards; and enterprise security solutions for identity and access management, secure mobility, organizational messaging, and network management and defense. The company serves commercial enterprises, regulated industries and government customers around the world. 

Media:
[email protected]

Investors:
[email protected]

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments.

Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes. Based on our recent positive Phase 1 topline data for SAB-142, we have seen accelerating momentum across the T1D landscape regarding the therapeutic potential of SAB-142.”

Recent Pipeline Developments

• In April 2025, SAB BIO concluded patient dosing in the last cohort of the Phase 1 clinical study of SAB-142.

Corporate Updates from Q1 2025

• FY 2024 budget initiatives are now contributing to cost savings focusing on improvements to the Company’s manufacturing processes for scaled-batch manufacturing. The Company anticipates these initiatives will contribute to continued efficiencies across the Company’s financial performance in 2025.
• The Company has successfully obtained a Qualified Person (QP) declaration for SAB BIO’s in-house CMC manufacturing process for SAB-142. This milestone represents a key cGMP compliance achievement enabling SAB BIO to meet European manufacturing standards for an investigational medical drug product (IMPD) designated for upcoming clinical trials in the EU. 

Q1 2025 Financial Results

• SAB BIO held cash and equivalents of $12.9 million as of March 31, 2025, compared to $20.8 million as of December 31, 2024.
• R&D expenses were $7.7 million and $8.1 million for the three months ended March 31, 2025 and March 31, 2024, respectively. The modest decline resulted from the fluctuation of priority spending for the SAB-142 program, a disease-modifying human hIgG aimed at preventing onset or disease progression of T1D.
• General and administrative expenses were $3.1 million and $4.2 million for the three months ended March 31, 2025 and March 31, 2024, respectively. This decrease was driven by reduced payroll related costs and professional fees in order to prioritize the Company’s continued research activities and development of its product candidates.
• Other income of $5.6 million and $6.4 million for the three months ended March 31, 2025 and March 31, 2024, respectively. This decrease was primarily due to the change in fair value of warrant liabilities and reduced net interest income.
• SAB BIO reported a net loss of $5.2 million and $5.0 million for the three months ended March 31, 2025 and March 31, 2024, respectively.

About SAB BIO

SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB BIO, visit: https://www.SAB.bio/ and follow SAB BIO on Twitter/X and LinkedIn.

Forward-Looking Statements

Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the data, development, clinical results, and efficacy of our T1D program and other discovery programs, the Company’s ability to raise additional funds on favorable terms, financial projections and future financial and operating results (including estimated cost savings and cash runway), the impact of existing or potential tariffs or changes to federal government priorities on the Company’s business and operations, and the outcome of current or potential future government and other third-party collaborations or funded programs.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Media Relations:
Kaelan Hollon
Vice President of Communications
[email protected]

Investor Relations:
Kevin Gardner
LifeSci Advisors
[email protected]

Chris Calabrese

LifeSci Advisors
[email protected]